Compare Manchester United PLC (MANU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Recursion Pharmaceuticals Inc — how do they compare? Manchester United PLC trades at $20.21 (market cap $3.51B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Manchester United PLC is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MANU | RXRX | |
|---|---|---|
Market Cap | $3.51B | $2.14B |
Volume | 412,769 | 30,789,535 |
Sector | Media | Health |
52-Week High | $24.19 | $6.79 |
52-Week Low | $15.20 | $2.84 |
Typical Hold Time | 109 Days | 22 Days |
Enterprise Value | $4.33B | $1.66B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.25, down 0.74% on the day, amid a bearish technical signal. The company reported a net loss of $33.02 million for 2025 despite revenue of $666.51 million, with negative profit margins and return metrics. Recent news highlights a valuation gap, with the market cap at $3.6 billion versus a Forbes estimate of $7.2 billion, while operational performance shows some improvement with a return to Champions League football.
The outlook remains cautious; while the valuation discount presents a potential opportunity, persistent losses and high debt levels pose significant risks. Analyst sentiment is mixed with a 40% buy rating, but fundamental challenges in achieving sustained profitability are key concerns for investors.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
